Effect of enzalutamide dose reduction on fatigue, cognition, and drug trough levels in patients with prostate cancer
Phase 2
Not yet recruiting
- Conditions
- Prostate Cancer
- Registration Number
- ACTRN12617000616370
- Lead Sponsor
- Macquarie University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- Male
- Target Recruitment
- 47
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie enzalutamide's impact on fatigue and cognition in prostate cancer patients?
How does enzalutamide dose reduction compare to standard therapy in managing prostate cancer symptoms?
Are there specific biomarkers that predict response to enzalutamide trough level adjustments in prostate cancer?
What adverse events are associated with enzalutamide dose reduction in phase II prostate cancer trials?
What combination therapies or alternative drugs show promise alongside enzalutamide for prostate cancer treatment?